All In Biotech

Drug Trial Radar · NCT03381274

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCLC

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

43

Actual

Start

May 8, 2018

Primary completion

May 24, 2021

Study completion Nov 6, 2026

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 21, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 101 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to investigate the safety, tolerability, and antitumor activity of novel combination therapies administered in participants with advanced EGFRm NSCLC.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • OleclumabBiological

    Participants will receive oleclumab in combination with osimertinib or AZD4635 as stated in the arms' description.

  • OsimertinibDrug

    Participants will receive osimertinib in combination with oleclumab as stated in the arms' description.

  • AZD4635Drug

    Participants will receive AZD4635 in combination with oleclumab as stated in the arms' description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose-limiting Toxicities (DLTs) in Part 1Time frame: From Day 1 to Day 28 after first dose of study drug
  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) in Parts 1 and 2Time frame: From Day 1 through 90 days of the last dose of study drug (approximately 37 months)
  3. Number of Participants With Abnormal Laboratory Parameters Reported as TEAEs in Parts 1 and 2Time frame: From Day 1 through 90 days of the last dose of study drug (approximately 37 months)
  4. Number of Participants With Abnormal Vital Signs and Physical Examination Reported as TEAEs in Parts 1 and 2Time frame: From Day 1 through 90 days of the last dose of study drug (approximately 37 months)
  5. Number of Participants With Notable QTc Interval in Parts 1 and 2Time frame: From Day 1 through 90 days of the last dose of study drug (approximately 37 months)
  6. Percentage of Participants With Objective Response (OR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in Part 2Time frame: From Day 1 through 90 days of the last dose of study drug (approximately 37 months)

Locations

13 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    La Jolla, California

  • Research Site

    San Francisco, California

  • Research Site

    Aurora, Colorado

  • Research Site

    New Haven, Connecticut

  • Research Site

    Atlanta, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Baltimore, Maryland

  • Research Site

    New York, New York

  • Research Site

    Houston, Texas

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Taichung, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.